drugset / Trial / NCT02685774

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers

NCT02685774

Phase 1 Completed 26 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/500 mg in healthy male volunteers.

Timeline

Start
2016-02
Primary completion
2016-03
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-395 Unknown 0.25 mg Oral
Subject CKD-395 Unknown 500 mg Oral
Subject Lobeglitazone Small molecule 0.5 mg Oral
Subject Metformin Small molecule 500 mg Oral